This group supports the Environmental Protection Agency’s (EPA) efforts to protect public health and the environment through the Residual Risk and Technology Review (RTR) process and recognizes the
need to develop stringent emissions standards to mitigate any potential hazards posed by Ethylene Oxide (EtO) emissions. However, they are also cautious of the impact these changes may have on the availability and timely delivery of biotherapeutics to patients who rely on them. Biotherapeutics, including vaccines, therapeutics, and other life-saving medications, play a crucial role in improving patient health outcomes and saving lives. For the biopharmaceutical industry, EtO sterilization is a critical process used to ensure product safety and efficacy. The EtO Response team raised several concerns regarding the potential impact of the proposed rule changes on the biotherapeutics market. This document discusses the concerns.
POI - Supply Partner
Viewing related articles
A vision for the biopharmaceutical industry’s inbound supply chain
Jul 2023 | Deliverable, Deliverables Report, POI - Supply Partner, Publication, Supply Partner
Building on the Strategic Framework published in 2021, this new document explains how it should be used. It includes a maturity/capability model to help companies identify how to develop so they can increase their maturity/capability level for any of the five strategic objectives. It is based on shared ‘real-world evidence’ from members who have contributed to how they achieve the level they are at with the people (organizations), systems (technologies) and process (operating procedures) they have invested in.
BioPhorum response to the Annex XV report on the proposal for universal PFAS restrictions
May 2023 | Deliverable, Deliverables Report, Drug Substance, Feedback to agency, Fill Finish, POI - Supply Partner, Supply Partner, Sustainability
The BioPhorum response to the Annex XV Report on the proposal for universal PFAS restrictions. It is considered by the BioPhorum collaboration that unless ECHA provide the biopharmaceutical manufacturing industry with appropriate exemptions or derogations to find, test and validate alternatives and execute a transition out of these materials (where alternatives are available), there will be a real threat to the global availability of critical vaccines and biotherapeutics.
Lead times best practice guide
Apr 2023 | Deliverable, Deliverables Report, POI - Supply Partner, Publication, Supply Chain Quality Management, Supply Partner
Industry needs a common language and consistent understanding to reduce risk and ensure that both parties fully understand the requirements of a transaction. This paper contains industry-agreed definitions for terms such as total lead time, inventory days, and economic order quantity.
Business continuity management in the biologic industry supply chain: a best practice guide
Mar 2023 | Deliverable, Deliverables Report, POI - Supply Partner, Publication, Supply Partner
This paper and the supporting questionnaire provides best practice guidance for effective business continuity management systems (BCMS) in the biologics supply chain. It can be used in two ways. First, as an introduction to BCMS and second, as guidance to benchmark companies’ current processes. It is based upon the framework in ISO 22301.
Long range planning – the final frontier, the audacious goal
Nov 2022 | Deliverables Report, Long Range Planning, POI - Supply Partner, Publication, Supply Partner
This paper summarizes the industry position and aims to start a strategic discussion on this situation. It will help ensure we have a common language and understanding across industry. Looking ahead, we will emphasize shared learning, best practices, and retrospective investigations to improve long-range planning processes
The future of the inbound supply chain: implementing electronic data exchange (EDE)
Oct 2022 | COVID 19, Deliverable, Deliverables Report, EDE/Digitization of the In-Bound Supply Chain, POI - Supply Partner, Publication, Supply Partner
This paper proposes that shared and electronic data exchange (EDE) is a cornerstone of collaboration and innovation in the supply chain. The paper aims to demystify EDE, set out its importance for supply chain effectiveness, capture its benefits and help people understand the practical enablers.
Current and near-future bioprocess supply situation and trends post COVID-19
Oct 2022 | COVID 19, Deliverable, Deliverables Report, POI - Supply Partner, Publication, Supply Partner
This paper provides an overview of the current and near-future bioprocess supply situation and trends. This research provides insights into how the industry has adjusted as the Pandemic begins to abate.
On time in full (OTIF) high level guidance
Jul 2022 | Deliverable, Deliverables Report, POI - Supply Partner, Publication, Supply Chain Quality Management, Supply Partner
This paper provides an introduction and a high-level view of on time in full (OTIF) so that when we use the acronym, we know how it is calculated and are all using it in the same way. It examines detail on the components of ‘Actual orders delivered’ and ‘Expected orders to be delivered’ and talks about the information included, actions to take and gives tips on how to best use each component.Â
Supply chain quality management optimal process and RACI
Jun 2022 | Deliverable, Deliverables Report, POI - Supply Partner, Publication, Supply Chain Quality Management, Supply Partner
These tools support sharing the optimal high-level steps to simplify a process and invite people into the discussion using a common language. The optimal process outlines the essential process steps and for each one lists the ‘who’ (i.e., which role) and the ‘how’ (i.e., what medium). The RACI supports people to understand where accountabilities and responsibilities lie.